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Abstract
One has to resort to allogenic source of bone grafts especially in filling up of large or 
multiple containable cavitary lesions, structural reconstruction of large circumferen-
tial osteoperiosteal defects, extensive spinal fusions for gross deformities, or extensive 
operative reconstruction after total joint replacements. These procedures demand an 
abundant quantity of bone material in which a patient’s (recipient’s) body cannot supply 
without significant morbidity and risks. At present most of the allogenic bone banks use 
deep-freezing or freeze-drying or radiation for long-term preservation. The techniques 
maintain sterility, reduce immunogenicity, and provide adequate structural integrity; 
however, such procedures reduce the bone-forming biological activity and are expen-
sive. We have worked for clinical translation of the basic research performed by Marshal 
Urist (1965–1994). After extensive experimental observations, we have been using 
partially decalcified allogenic bone as grafts in clinical cases since 1978. Favorable out-
come has been observed in benign cystic lesions, wide-gap grafting, and spinal fusions. 
Minimum follow-up for declaring “success” or “failure” of the procedure was 2 years 
after implantation.
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1. Introduction
Bone grafting is a standard orthopedic procedure performed in clinical practice. Autogenous 
graft is the gold standard and the preferred graft used. However, allograft bone continues to 
play an important role in many orthopedic reconstructive procedures. One has to resort to 
the allogenic sources especially in filling up of large or multiple containable cavitary lesions, 
structural intercalary reconstruction of large circumferential osteoperiosteal defects, extensive 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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spinal fusion for gross deformities or severe instabilities especially in children, and repeat sur-
geries after total joint replacements. These procedures demand an abundant quantity of bone 
which the recipient’s body cannot supply without significant morbidity and risks. At pres-
ent popularly allogenic bone is preserved by deep-freezing or freeze-drying or by radiation 
for long-term preservation. These techniques have been shown to maintain sterility, reduce 
immunogenicity, and provide adequate structural integrity; however, such procedures also 
reduce the bone-forming biological activity and are expensive (Table 1). Autoclaving and 
radiation completely destroy bone inductive principles.
One of the most exciting works during the latter half of the twentieth century (1965–1994) has 
been the clinical translation of the basic research performed by marshal Urist [1, 2].
After extensive experimental work [3, 4], we have been using partially demineralized 
allogenic bone (decal-bone) as grafts in clinical cases. For preparation and preservation of 
allogenic bone graft, we used the techniques described by Urist (1965–1987). We aimed at 
removal of approximately 50% of mineral from the graft, thus retaining adequate structural 
integrity (Table 2). We used this material since 1978, and we closely observed the clinical 
results on long-term bases in 67 benign cystic lesions, 32 wide-gap graftings, and 11 posterior 
A. Treatment with 0.6 MHcl:
• Removes mineral and exposes BMP and other growth factors on matrix
• Opens and cleanses vascular, Haversian, Volkmann channels, and lacunar spaces of cells and debris
• Reduces antigenicity, chemosterilizes, and is virucidal
B. Treatment with ethanol:
• Preserves without denaturing the bone morphogenetic protein (BMP) and other osteoinductive principles (OIP), 
chemosterilizes, and is virucidal
• Leaches out fat ex vivo
• These processes as a rule are done by the host scavenger cells in vivo in un-demineralized bone grafts
Table 2. Processing of allogenic decal-bone.
Fresh 
autogenous
Fresh/unprocessed 
allogenic
Frozen  
freeze-dried  
allogenic
Partially 
decalcified
Deproteinated 
allogenic
Osteoinduction ++++ +++ +++ ++++ 0
Osteoconduction +++ ++ ++ +++ ++
Osteogenic ++ 0 0 0 0
Immunogenicity 0 +++ ++ ?+ 0
Mechanical
strength
+++ +++ ++ ++ ++
Cost ?+ + +++ + +++
Frozen grafts require thawing, freeze-dried grafts require hydration before implantation, and the unused graft cannot 
be re-preserved.
Table 1. Commonly used bone grafts in clinical orthopedics.
Bone Grafting - Recent Advances with Special References to Cranio-Maxillofacial Surgery44
or posterolateral spinal fusion. Minimum follow-up for declaring “success” or “failure” of the 
grafting procedures was 2 years after implantation. We prefer to use the expression of “decal-
bone” because the whole process of decalcification is performed in vitro.
2. Preparation of allogenic “decal-bone” graft
Human bones were obtained from freshly (posttraumatic) amputated extremities, under 
strict aseptic operation theater conditions. Soft tissues and periosteum were removed from 
the bones using sharp instruments. After a minimum of three washings with normal saline, 
the bones were placed and immersed in 0.6 M HCI solution for 3–5 days in a domestic refrig-
erator. The solution was changed every 24 hours. The partially decalcified bone was washed 
with normal saline to remove any traces of acid, sealed in 80–90% ethanol, and kept in a 
domestic refrigerator at about 4–6°C (Figures 1 and 2). The stored bone was used between 1 
and 12 months of preservation. Osteoporotic bone from old persons would be ready by the 
third day; however, fully mineralized bone from athletic or healthy persons may take 5 days 
for achieving 50–40% decalcification. Bone obtained from total knee replacements in the oper-
ating rooms was another material processed for use as decal-bone.
When required for implantation, the preserved bone was washed thoroughly with normal 
saline. The superficial surface of graft was pared using a sharp scalpel, and it was cut to 
the required size to give a snug fit in the host bed for structural grafting, generally fixing 
to the host bone using an intramedullary nail. For filling large cystic cavities of bone, the 
decal-bone was cut like matchstick silvers with thickness and width of 4–6 mm and washed 
with normal saline. The cavities after thorough curettage were compactly packed with the 
matchstick graft.
For spinal fusions the recipient bed was decorticated, and abundant graft was placed oriented 
along the long axis of the spine. In cases with gross mechanical instability, a suitable implant 
with multi-segmental fixation was employed as an adjunct. Standard operative principles for 
such extensive procedures were followed with modifications to suit individual requirements.
For giant cell tumors of bone (GCT) prior to 1986, en bloc resection and structural reconstruc-
tion was performed as a standard procedure. We had an opportunity to observe the behavior 
of large allogenic segmental graft used for such patients. Global observation however advised 
less aggressive joint-sparing intralesional procedures since approximately 1987.
Currently for all containable cystic lesions including GTC, we use and recommend the follow-
ing steps for grafting:
I. Perform thorough intralesional curettage through an adequate window.
II. Aspirate the debris completely.
III. Fill up the cavity with hydrogen peroxide for 3 minutes, and clean the cavity with nor-
mal saline.
IV. Fill the cavity with absolute ethanol (80–90%) for 3 minutes.
V. Remove ethanol and wash with normal saline.
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VI. Do compact filling of the cavity with decal-bone grafts.
VII. After wound closure protect the limb with suitable cast, and follow the standard post-
operative care.
This routine has appreciably reduced the incidence of infection and recurrence, and the suc-
cess rate has markedly improved.
2.1. Cytological and histological observations
In addition to clinical and radiological assessment, postimplantation observations were made 
by (i) periodic fine-needle aspiration cytology (FNAC) from the graft and perigraft area, 
Figure 1. After complete decalcification, the bone (radius in picture) becomes soft like leather.
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(ii) by periodic core biopsy of the graft after tetracycline administration, and (iii) by histologi-
cal studies of the retrieved graft in cases of reoperation.
2.1.1. Observations
Cavitary cystic lesions: the observations regarding cystic lesions are listed in Table 3. The 
success after curettage and bone grafting was uneventful in 60% of cases of giant cell tumor 
(GCT), in 75% of cases of aneurysmal bone cyst (ABC), and in 85% of cases of unicameral 
bone cyst (UBC) Figure 3. Further success by supplementary curettage and bone grafting was 
obtained in 10% of cases of GCT, 25% of ABC, and 15% of UBC. Supplementary bone grafting 
was required because of unexplained resorption of the graft or low-grade infection leading 
to sequestration and resorption of the graft. Six cases of GCT failed because of uncontrolled 
Figure 2. Partially decalcified bone stored in ethanol.
Pathology Success Sup. success Failure
Typ. giant cell tumor 18 60% 10% 30%
Aneurysmal bone cyst 21 75% 25%
Unicameral bone cyst 11 85% 15%
∙ Fibrous defect 6 6
∙ Solitary chondroma 3 3
∙ Chod. myxoid fibroma 2 2
∙ Poly-OFD 4 3 1
∙ Multiple enchondromas 2 1 1
∙ Number is too small to express as valid percentage.
Poly-OFD = polyostotic fibrous dysplasia.
Table 3. “Cystic lesions” of bone (67) treated by curettage and allogenic decal-bone grafting.
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infection (three cases) and massive recurrence of tumor (three cases). All patients of solitary 
osseous lesions healed successfully. Polyostotic fibrous dysplasia (4), multiple fibrous defects 
(6), enchondromas (3), chondromyxoid fibroma (2), and enchondromatosis (2) by their bio-
logical nature may need reoperation for an increase in the size of the lesions which were 
insignificant at the time of the first surgery. One patient of fibrous dysplasia had to undergo 
a second operation for a new lesion, and one patient of enchondromatosis is awaiting surgery 
for the additional area (Figure 4).
3. Intercalary structural bone grafts
Observations regarding 32 cases of structural bone grafts used for large osteoperiosteal gaps 
are summarized in Table 4. The largest group was 28 cases of giant cell tumors, 40% of these 
obtained uneventful success (Figure 5), 38% needed supplementary operation in the form of 
Figure 3. A recurred giant cell tumor of distal femur with pathological fracture. The healed status achieved by 
intralesional curettage and decal-bone grafting following 12 years.
Figure 4. A case of polyostotic fibrous dysplasia. The cyst in the trochanteric area remained healed after curettage and 
decal-bone grafting. After about 14 years of gap, another cyst in the supra-acetabular region needed treatment.
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further autologous bone grafts for areas of non-union at host graft junctions or for pseudar-
throsis in the intermediate part of the graft 20%, for control of infection, or for a combination 
of these factors (18%).
Six patients were considered a failure because the reconstruction failed. Two had recur-
rence of tumor, one had uncontrolled infection, and these ended up in amputations. In three 
patients despite two attempts at supplementary grafting, the areas of pseudarthrosis did not 
heal; these patients accepted an orthosis till further decision. One case of malignant fibrous 
histiocytoma failed because of recurrence of tumor within 4 months of limb salvage attempt.
Of the 11 patients of posterior or posterolateral spinal fusion, 10 were considered to have 
obtained satisfactory osseous fusion based upon clinical assessment and stress X-rays done 
12–24 months after the operation (Figure 6). One young nurse who had posterior fusion along 
with Steffi’s fixation at L3–L4 for spondylolisthesis was considered a failure because of the 
implant breakage observed 2 years after operations.
3.1. Cytological and histological observation
Fine-needle aspiration cytology (FNAC) was done from the perigraft region (in 20 patients) 
between the 10th and 40th day after grafting. The FNAC showed high cellularity composed of 
Pathology Success Supp. success Failure
Giant cell tumor 28 40% 38% 28%
∙ Aneurysmal bone graft 1 1 – –
∙ Unicameral bone graft 1 1 – –
∙ Central fibrosarcoma 1 – 1
∙ Traumatic extrusion 1 1 – –
∙ Number is too small to express valid percentage.
Table 4. Large osteoperiosteal gaps (32) and structural grafts (1979–1999).
Figure 5. Intercalary reconstruction after en bloc resection of giant cell tumor of distal femur. Note gradual incorporation 
and remodeling as observed in the 12-year follow-up.
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polymorphs, lymphocytes, and macrophages between 10 and 20 days. The cellularity gradu-
ally reduced with relative increase in the number of lymphocytes. By the 40th postimplantation 
day, the macrophages were practically absent, and one could see appreciable osteogenic activ-
ity by the presence of osteoblasts and osteoclasts. No cellular immune reaction was discernable.
Periodic core biopsy in early stages and biopsy of the graft in patients who required a sec-
ond operation showed histological and tetracycline fluorescence evidence of neo-osteogenesis 
between 6 and 12 weeks. The fluorescence in the implanted allogenic bone was quantitatively 
the same as the bone of a patient’s iliac crest in specimens available 12 months after the grafting.
3.2. Discussion
Contents of bone grafts and their roles: In general calcium hydroxyapatite, the predomi-
nant mineral in bones provides an inert framework providing mechanical stability and offer-
ing a lattice work for penetration of neocapillaries, reparative tissues, and osteoconduction 
(Table 5). Only the most superficial bone-forming cells in fresh autografts which survive get-
ting nutrition by tissue perfusion provide direct osteogenic activity. In allografts no viable 
cells are expected; however, the debris of dead cells act as the most potent immunogenic agent. 
Organic matrix provides the most potent bone morphogenetic (bone induction principles) 
Figure 6. A child having tuberculosis of the spine involving multiple vertebrae: posterior spinal fusion was performed 
using allogenic decal-bone. Note the incorporation of the graft with remodeling during a 3-year follow-up.
Ca hydroxyapatite Mechanical stability
Autogenous surviving cells Osteogenesis
Allogenic non-surviving cells Immunogenesis
Matrix Bone morphogenetic agents(weak mechanical strength)
Table 5. Contents of bone graft and their role.
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agent. Its viability however depends upon the influence of processes of allograft preparation 
and preservation [5–10].
Bone graft incorporation: The biological process of incorporation of bone grafts is practically 
similar to that of a fracture healing. Under favorable environment, the following major steps 
occur in a cascadal fashion from the time of placement of the bone graft in the recipient bed to its 
incorporation and remodeling according to Wolff’s law: (i) hematoma formation and its orga-
nization by invasion of neocapillaries surrounded by perivascular pluripotent mesenchymal 
cells; (ii) osteoclastic and phagocytic resorption of nonviable mineral (calcium hydroxyapatite), 
cellular debris and marrow fat, and tunneling of the graft-making channels for ingrowth and 
propagation of neocapillaries and osteoprogenitor cells; (iii) conversion (tissue engineering) 
of osteoprogenitor cells to osteoblastic cells under the influence of local osteoinductive agents 
(bone morphogenetic protein, other inductive agents, and growth factors present in the organic 
matrix of the bone graft) and the platelets. Laying down of the new bone (neo-osteogenesis) on 
the surface of matrix framework and along the vascular spaces/channels; and (iv) remodeling 
of the newly formed bone to conform to the trabecular pattern along the lines of functional 
loading and stress (according to Wolff’s law). These events are a slow process; the grafted area 
needs protection with repetitive physiological axial or functional loading. The most challeng-
ing clinical condition of structural (intercalary) bone grafting for large osteoperiosteal gaps in 
the lower limb may take 2–4 years for adequate incorporation permitting unprotected loading 
[11, 12]. The mechanical strength of the reconstruct is weak for 1 and 1/2 to 2 years, after which 
the strength increases by more neo-osteogenesis. The least time is taken in a cavitary pathology 
which offers a very large osteogenic bed and copious surface for intimate contact with the graft 
[13–15]. As incorporation takes place from periphery to the center, the time taken for large 
cavities and large grafts is correspondingly higher. In un-demineralized cortical (e.g., fibula) 
graft, 20–30% (deepest sector) of the grafted bone may never get incorporated; it may stay 
incarcerated surrounded by newly formed bone.
By HCL decalcification we aimed at the removal of nearly 50% of mineral, thus providing 
adequate structural integrity. The said treatment removed all cell debris and fat providing 
opened-up channels for ready penetration of neocapillaries and perivascular mesenchymal 
cells. Acid demineralization also removed the mineral from the surface of the bone, along the 
vascular channels, and on the lacunar spaces, thus exposing the matrix for intimate contact 
with the invading perivascular tissues, and facilitated the interaction between the graft matrix 
(most active osteoinductive principle) and the pluripotent mesenchymal cells from the host. 
The technique used by us does not destroy the biological osteoinductive property of the bone 
matrix.
Immunogenicity of allogenic bone is now better understood. Fresh unmatched and untreated 
allogenic bone inevitably evokes an immune response in the host. The immune response in 
general is delayed and mild and develops slowly; however, it results in “unexplained” graft 
resorption and delay or failure in its incorporation. In clinical practice deep-freezing, freez-
ing, freeze-drying, and irradiation are currently employed to reduce immunogenicity. Pure 
BMP from an allogenic source or even a xenogenic source is considered to have negligible 
immunogenicity. We feel that a simple treatment of allogenic bone by HCL decalcification 
and ethanol preservation practically eliminates the antigenic material (cells and debris) to 
permit unhindered incorporation in clinical practice as observed in our cases. Overall analysis 
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in our clinical material has been approximately 80–90% successful for benign cavitary lesions; 
for impaction grafts in revision joint surgeries, 50–70% success for structural reconstruction 
in circumferential osteoperiosteal gaps; and 70–90% clinical success in extensive spinal fusion. 
Supplementary procedures for obtaining success in difficult cases, especially for osteoperi-
osteal gaps, are an accepted norm in 20–30% of cases. The success rate in our clinical cases 
is compatible with the observations of the outcome where allogenic bone was used from 
more sophisticated bone banks. Allogenic bone graft is a rational option when the recipient’s 
patient owns bones that are inherently defective (e.g., fibrous dysplasia, enchondromatosis).
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